M Holdings Securities Inc. Buys 3,429 Shares of Amgen Inc. $AMGN

M Holdings Securities Inc. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,429 shares of the medical research company’s stock, valued at approximately $1,584,000.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. boosted its position in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the period. State Street Corp increased its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after acquiring an additional 605,928 shares during the period. Bank of America Corp DE bought a new stake in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Finally, Amundi raised its stake in shares of Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after acquiring an additional 512,883 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 1.0%

Shares of AMGN stock opened at $465.23 on Tuesday. The stock has a 50 day moving average of $423.08 and a 200 day moving average of $378.80. The company has a current ratio of 1.48, a quick ratio of 1.13 and a debt-to-equity ratio of 3.60. The stock has a market cap of $251.52 billion, a P/E ratio of 26.99, a P/E/G ratio of 3.47 and a beta of 0.43. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the previous year, the company posted $5.64 earnings per share. Amgen’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, sell-side analysts expect that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is 58.47%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMGN. Robert W. Baird upped their target price on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Cantor Fitzgerald increased their price objective on shares of Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Sanford C. Bernstein raised their target price on shares of Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a report on Wednesday, November 4th. Finally, Bank of America boosted their target price on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $422.76.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.